期刊
JOURNAL OF CHEMICAL INFORMATION AND MODELING
卷 60, 期 2, 页码 1028-1041出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jcim.9b00802
关键词
-
类别
资金
- National Council for Scientific and Technological Development (CNPq), Brazil
- Coordination for the Improvement of Higher Education Personnel (CAPES), Brazil
- Sao Paulo Research Foundation (FAPESP), Brazil [2013/07600-3]
- Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP) [13/07600-3] Funding Source: FAPESP
A virtual screening conducted with nearly 4 000 000 compounds from lead-like and fragment-like subsets enabled the identification of a small-molecule inhibitor (1) of the Trypanosoma cruzi cruzain enzyme, a validated drug target for Chagas disease. Subsequent comprehensive structure-based drug design and structure-activity relationship studies led to the discovery of carbamoyl imidazoles as potent, reversible, and competitive cruzain inhibitors. The most potent carbamoyl imidazole inhibitor (45) exhibited high affinity with a K-i value of 20 nM, presenting both in vitro and in vivo activity against T. cruzi. Furthermore, the most promising compounds reduced parasite burden in vivo and showed no toxicity at a dose of 100 mg/kg. These carbamoyl imidazoles are structurally attractive, nonpeptidic, and easy to prepare and synthetically modify. Finally, these results further advance our understanding of the noncovalent mode of inhibition of this pharmaceutically relevant enzyme, building strong foundations for drug discovery efforts.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据